Jefferies Stick to Their Buy Rating for Intra-Cellular Therapies
Investing.com
Published Sep 20, 2021 08:27AM ET
Jefferies (NYSE:JEF) analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) on Saturday, setting a price target of $70, which is approximately 103.73% above the present share price of $34.36.
Tsai expects Intra-Cellular Therapies to post earnings per share (EPS) of -$0.85 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Intra-Cellular Therapies, with an average price target of $51.
The analysts price targets range from a high of $70 to a low of $44.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $19.01 million and a net profit of -$69.14 million. The company's market cap is $2.79 billion.
According to TipRanks.com, Jefferies analyst Andrew Tsai is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.2% and a 38.24% success rate.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.